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Rabbit and mouse anti-Torpedo acetylcholine receptor antibodies cross-reacted partially with the highly 
phosphorylated protein, phosvitin. We have selected an anti-Torpedo acetylcholine r ceptor monoclonal 
antibody which binds specifically to phosvitin; this binding is inhibited by acetylcholine r ceptor. These 
findings suggest that a phosphorylated amino acid residue may be a part of the determinant on the 
acetylcholine r ceptor ecognized by this monoclonal antibody. 
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1. INTRODUCTION 
Two molecular forms of acetylcholine receptor 
(AChR) are found in skeletal muscle. In the em- 
bryonic myotube the AChR molecules are 
uniformly distributed over the cell surface in a low 
density. In the adult muscle, AChR is almost ex- 
clusively present in the subsynaptic membrane in a 
densely packed form [l-4]. Those two receptor 
forms, referred to as extrajunctional receptor 
(EJR) and junctional receptor (JR), respectively, 
differ in several properties such as metabolic turn- 
over time [5,6], channel open time [7,8] and some 
pharmacological properties [9, lo]. 
In Torpedo, there is a difference in the degree of 
phosphorylation of junctional (adult) and extra- 
junctional (newborn) AChR. JR appears to be 
more heavily phosphorylated than EJR. This has 
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been related to some physico-chemical characteris- 
tics of the two molecules [111. Torpedo JR is more 
heat-resistant than EJR and has a lower isoelectric 
point. The latter is also true for the two forms of 
muscle AChR [12]. After treatment of adult 
Torpedo AChR with alkaline phosphatase, there is 
a decrease in heat resistance, and the isoelectric 
point becomes 0.1 pH units higher; these are pro- 
perties similar to those of the immature Torpedo 
AChR [ll]. 
AChR from electric organ of adult Torpedo 
californica contains phosphorylated amino acids 
[13], and the receptor itself is a specific substrate 
for phosphorylation by an endogenous receptor 
kinase [ 14- 161. To assess whether phosphorylated 
amino acid residues participate in antigenic deter- 
minants in AChR and contribute to its antigenic 
specificity, we analyzed the immunological reac- 
tivity of our monoclonal anti-AChR antibodies 
(mcAbs) with two highly phosphorylated proteins, 
phosvitin and casein. Here, we describe an anti- 
AChR mcAb prepared against purified adult 
Torpedo receptor, which reacts specifically with 
phosvitin. This suggests that a phosphorylated 
amino acid residue may be a part of the determi- 
nant on AChR recognized by this mcAb. 
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2. MATERIALS AND METHODS 
Casein and phosvitin were purchased from 
Sigma (St Louis MO). Radioiodination of goat- 
anti-mouse or anti-rabbit immunoglobulins and of 
AChR was performed by the chloramine T method 
F71. 
2.1. Antisera preparation 
Rabbit anti-casein and rabbit anti-phosvitin an- 
tisera were obtained following 3 intradermal injec- 
tions at 20 day intervals of 1OOpg immunogen 
emulsified in complete Freund’s adjuvant. Rabbit 
anti-AChR [ 181, mouse anti-AChR [ 191 and anti- 
AChR mcAbs [20] were prepared as described. We 
used ascitic fluids as the source of mcAbs. 
2.2. Solid phase radioimmunoassay (SphRIA) 
This test was performed as in [21]. For binding 
experiments, 100~1 of the test antigen (50pg/ml) 
in phosphate-buffered saline (PBS) was added to 
the wells of 96-well-polystyrene plates and in- 
cubated overnight at 4°C. The plates were then 
washed with PBS containing 1% (w/v) bovine 
serum albumin (BSA) and this wash buffer was left 
in the wells for 2 h at room temperature. Of each 
mcAb or antiserum, 75 ~1 properly diluted in 1% 
PBS-BSA, was added to the wells and incubated 
for 2 h at room temperature. After washing, 50 pl 
‘*Q-goat anti-mouse or anti-rabbit im- 
munoglobulin (corresponding to the antibody 
tested), diluted in 1% PBS-BSA to give a total of 
lo5 cpm, was added. After washing with PBS, 
wells were dried, cut and counted in an auto- 
gammacounter. Non-immune sera, antisera 
against unrelated antigens and a mcAb with an 
unrelated specificity were used as controls. For in- 
hibition experiments the antibody was prein- 
cubated with the tested inhibitor for 12 h at 4°C 
and then added to the antigen-coated plates. The 
test was continued as described above for binding 
experiments. 
2.3. Radioimmunoassay (RIA) with “‘I-AChR 
This test was performed as in [21]. 25 ,ul of lz51- 
AChR [2.5 ng in 0.01 M Tris-HCl buffer (pH 7.4) 
and 0.1% Triton X-100, containing 1 mg/ml 
BSA], was incubated with 25 pl mcAb, properly 
diluted in PBS, containing 5% (v/v) normal mouse 
serum (NMS), for 1 h at 37’C, then precipitated 
by goat-anti-mouse immunoglobulins and 
counted. For inhibition experiments, the test in- 
hibitor was preincubated with the antibodies, as 
described above for SphRIA, prior to the addition 
of the radiolabelled AChR. 
3. RESULTS 
Both rabbit and mouse anti-AChR antisera bind 
in SphRIA to phosvitin, although to a much lesser 
extent than their binding to the homologous im- 
munogen, AChR (table 1). Rabbit anti-AChR an- 
tiserum did not bind at all to casein, whereas weak 
binding is observed with mouse anti-AChR an- 
tiserum. Rabbit antisera agqinst casein and 
phosvitin failed to cross-react with Torpedo 
californica AChR. Also, rabbit anti-phosvitin an- 
tiserum does not cross-react with casein; limited 
cross-reactivity between rabbit anti-casein an- 
tiserum and phosvitin is observed. 
3.1. Binding of mcAbs 
Our anti-Torpedo AChR mcAbs were tested 
here for their reactivity with casein and phosvitin. 
Table 1 
Binding of polyclonal antisera to phosvitin, casein and 
AChR 
Antiserum Dilution Binding toa 
Phosvitin Casein AChR 
Rabbit anti-AChR l/10 9320 - 22340 
Mouse anti-AChR 
Rabbit anti-casein 
1 
1100 1490 - 20780 
11000 590 - 23 650 
/lO 10300 5020 13650 
/loo 6400 1480 16890 
/lOOO 980 - 14630 
A0 3750 10450 - 
l/100 600 13600 - 
l/1000 - 6640 - 
Rabbit 
anti-phosvitin l/10 10740 - - 
l/100 7720 - - 
l/1000 6380 - - 
a Experiments were performed in triplicates 
Results are expressed in average cpm after subtraction of
the value obtained with control normal serum 
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Fig. 1. Binding (solid phase radioimmunoassay) of anti- 
AChR mcAbs to phosvitin: (0) mcAb 5.46; (0) mcAb 
5.14; (A) control, an mcAb of a non-related specificity. 
About 30 different mcAbs from hybridizations 
no.1 and 5 were tested. The characterization of 
some of these mcAbs is described in [20-231, None 
of the mcAbs exhibited significant binding to ca- 
sein. Two mcAbs, 5.46 and 5.14, bound to 
phosvitin (fig. 1). However, of the two, 5.46 show- 
ed a much higher binding, which was constant and 
highly reproducible throughout all experiments, 
while 5.14 gave somewhat variable results. No 
significant binding was detected below l/500 dilu- 
tion of 5.14 as&tic fluid. In order to determine 
Table 2 
Binding of mcAb 5.46 and mcAb 5.14 to phosvitin and 
polygIutamic acid 
mcAb Dilution Binding to @pm) 
Phosvitin PGA’ 
5.46 l/100 27 300 3100 
l/500 12800 1380 
5.14 l/100 13800 6000 
l/500 4700 1800 
URSb l/loo 3920 2480 
l/500 1140 960 
a Poly~ut~ic acid 
b McAb with a non-related specificity 
Table 3 
Specificity of the binding of mcAb 5.46 to phosvitin’ 
Inhibitor Inhibition by 
@w/ml) 
AChR Phosvitin 
wm % In- cpm 070 In- 
hibition hibition 
- 11280 - liu30 - 
0.001 10600 6 7780 39 
0.01 8700 23 6150 45 
0.025 7220 36 n.d. n.d.b 
0.1 4400 61 s190 54 
1 n.d. n.d. 4060 64 
a Inhibition of the binding in solid phase 
radioimmunoassay of mcAb 5.46 (l/500) to phosvitin 
by AChR and phosvitin 
b n.d., not done 
whether the binding to phosvitin was due to elec- 
trostatic interactions with the negative charges on 
phosvitin, we tested the binding of these two 
mcAbs to negatively charged polygiutamic acid 
(PGA). McAb 5.46 showed no sig~fic~t binding 
to PGA (table 2). However, mcAb 5.14 exhibited 
binding to PGA which amounted to about 35tllo f 
the binding obtained with phosvitin. 
3.2. rn~jbition experiments 
Preincubation of mcAb 5.46 with AChR or with 
phosvitin resulted in inhibition of the mcAb bind- 
ing to phosviti~ in a dose-dependent way (table 3). 
However, preincubation with phosvitin does not 
prevent the binding of 5.46 to AChR in either RIA 
or SphRIA. Control proteins did not affect the 
binding of 5.46 to phosvitin. 
4. DISCUSSION 
This study was designed to find an anti-AChR 
monoclonal antibody directed against an antigenic 
determinant containing a phosphorylated amino 
acid. Our strategy was to search for an anti-AChR 
mcAb which could react with highly phosphoryl~ 
ated non-related proteins such as casein and phos- 
vitin. Early screening with polyclonal anti-AChR 
antisera showed cross-reactivity with either casein 
or phosvitin. Both rabbit anti-AChR and mouse 
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anti-AChR bound to phosvitin, while only mouse 
anti-AChR gave a weak positive reaction with ca- 
sein. Normal rabbit and mouse sera did not react 
with either casein or phosvitin. Screening of anti- 
AChR mcAbs failed to show reactivity with casein. 
However, in screening mcAbs from another 
hybridization (no.6; unpublished) obtained from a 
fusion of spleen cells of mice immunized with 
AChR-enriched Torpedo californica membranes, 
we found one mcAb (6.27) which exhibited a very 
strong binding (up to l/10’ dilution) to casein. 
This mcAb exhibited some cross-reactivity with 
phosvitin (up to l/l@) but did not bind AChR at 
all, and was therefore not appropriate for our pre- 
sent study. McAb 5.46, shown to be directed 
against a conformation-dependent antigenic deter- 
minant on AChR [23], was found to cross-react 
with phosvitin. The binding of mcAb 5.46 to 
phosvitin, although lower than with AChR, was 
nonetheless very’significant. The different binding 
of 5.46 towards phosvitin and AChR may suggest 
either that 5.46 binds to antigenic determinants on 
AChR and phosvitin which are similar, but not 
identical, or alternatively, that the antigenic deter- 
minants are identical but differ in the structures 
that surround them. Such a determinant on 
phosvitin may not be immunogenic or may repre- 
sent only a small percentage of the total an- 
tibodies. This may explain why we did not observe 
cross-reactivity of anti-phosvitin antisera with 
AChR. 
The fact that phosvitin is a very acidic protein 
suggested to us that charge interactions could play 
a significant role in the binding of mcAb 5.46 to 
phosvitin. This was ruled out by the fact that 
mcAb 5.46 is not significantly different in its 
isoelectric point from the other anti-AChR mcAbs 
tested, and by its inability to bind to polyglutamic 
acid coated wells. The charge was more likely an 
important component in the binding of another 
anti-AChR mcAb (5.14) to phosvitin. However, 
we could not rule out the possibility that 5.14 also 
recognizes some structure on phosvitin. 
We screened our anti-AChR mcAbs with casein 
and phosvitin to determine whether these two 
highly phosphorylated proteins could be used to 
select antibodies directed against antigenic deter- 
minants involving phosphorylated groups. 
Although mcAb 5.46 binds phosvitin specifically, 
we could not unequivocably demonstrate that this 
cross-reactivity between phosvitin and AChR in- 
volves a phosphorylated group. Phosphoserine 
and phosphothreonine, products of the kinase 
reaction, did not inhibit mcAb 5.46 binding to the 
AChR (not shown). However, this does not rule 
out the possibility that these phosphorylated 
amino acids are part of the cross-reacting deter- 
minant .
The degree of phosphorylation may be one of 
the differences between EJR and JR; this was sug- 
gested to account for differences between neonatal 
and adult AChR of Torpedo marmorata [ 111. It 
should be noted that in binding studies of various 
anti-AChR mcAbs to rat muscle homogenates at 
different ages, we observed that mcAb 5.46 bound 
to membrane-bound AChR only from rats > 17 
days of age. However, all the other mcAbs bound 
to membranous AChR at all ages (in preparation). 
These results suggest hat mcAb 5.46 recognizes an 
antigenic determinant involving a phosphorylated 
amino acid which appears late during muscle 
development. 
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